ALK and neuroblastoma: Although the standard route for the evaluation of novel compounds is through early phase clinical studies in relapsing or treatment-refractory disease, there is strong preclinical rationale for the combination of ALK inhibition with up-front chemotherapy in ALK-positive neuroblastoma patients.